Resumo:
The increase in socio-environmental changes has encouraged the search for ecologically
friendly inputs in the global industry. In this context, phycobiliproteins from microalgae have
become an asset of great interest to the pharmaceutical, cosmetic, and food industries due to
their diverse biological activities, color/fluorescence, non-toxicity, and origin from renewable
sources. This work aims to demonstrate the value of this protein for pharmaceutical purposes,
as it is applied to healing, as well as the development of a release system capable of maintaining
the molecule's stability in aqueous media. To this end, a patent search for C-FC related to
different drug delivery systems provided a basic overview of the market and future projections.
In addition, delivery systems were developed to incorporate C-FC for healing use. Patent
prospecting has shown that technological maturity concerning the topic is growing, and the
presence of medicines on the market with bioactivity is not yet observed; the reasonable market
projections encourage investment in research and development in this area. In addition, it was
observed that C-FC can be incorporated into different delivery systems, with its therapeutic
application being more predominant in anticancer drugs. In the development of the release
systems, it was possible to observe that liposomes were not able to encapsulate the active
ingredient due to the method used to make the system, but Synperonic® 127 and Carbopol®
996 gels were able to incorporate C-FC, the former being able to promote greater stability to
the active ingredient. The results indicate that the formulation obtained may have woundhealing potential.
